Navigation Links
Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego
Date:10/27/2009

SAN DIEGO, Oct. 27 /PRNewswire-FirstCall/ -- Data from a phase II study demonstrated that oral NKTR-118 improved lower gastrointestinal dysfunction by increasing the frequency of bowel movements in patients with opioid-induced constipation, while simultaneously preserving opioid-mediated analgesia. NKTR-118, an oral peripherally-acting opioid antagonist, is an investigational product candidate in clinical development for the treatment of opioid-induced constipation.

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO )

In the phase II double blind, randomized, placebo-controlled study of 208 patients with opioid-induced constipation, NKTR-118 achieved the primary endpoint of change from baseline in spontaneous bowel movements (SBMs). Patients receiving either 25 mg or 50 mg of oral NKTR-118 once daily had a significantly greater change from baseline in SBMs during the first week of treatment than patients receiving placebo. The mean change from baseline in SBMs per week for patients receiving 25 mg NKTR-118 was 3.6 versus 1.9 in the placebo group (p= 0.002). Patients receiving 50 mg NKTR-118 had a mean change from baseline in SBMs per week of 4.4 versus 1.9 in the placebo group (p=0.0001). The increase from baseline in SBMs versus placebo averaged over the four-week treatment period was significant for both the 25 mg (p=0.002) and 50 mg (p<0.0001) dose groups. Results for the 5 mg dose of NKTR-118 were not significant.

The study also showed that there was a statistically significant difference in median time to first SBM for patients in the 25 mg and 50 mg dose cohorts as compared to placebo. Median time to first SBM for patients in the 25 mg dose cohort was 6.6 hours as compared to placebo which was 48.6 hours (p=0.001), and for patients in the 50 mg dose cohort, median time to first SBM was 2.9 hours as compared to placebo,
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
2. Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users
3. Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study
4. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
5. Delcath Systems, Inc. Completes Phase III Study Enrollment
6. AFFiRiS AG - Encouraging Results From Phase I Studies of two Alzheimers Candidate Vaccines Trigger a EUR 10 Million Milestone Payment
7. Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections
8. Data from Jazz Pharmaceuticals First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences
9. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
10. Paratek Pharmaceuticals Signs Worldwide License and Commercialization Agreement for PTK 0796, Broad-Spectrum Oral and IV Antibiotic in Phase 3
11. TOPICA Announces Positive Phase 2 Clinical Results for Luliconazole, a Potent Topical Antifungal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... AVIV, Israel , May 6, 2015  Galmed ... biopharmaceutical company focused on the development and commercialization of ... diseases and cholesterol gallstones, announced today that it will ... 13, 2015 to discuss results for the period ended ... current developments with respect to its clinical program for ...
(Date:5/6/2015)... , May 6, 2015 Neuralstem, Inc. (NYSE ... technology to develop small molecule and cell therapy treatments ... Jonathan Lloyd Jones to the position of ... Mr. Lloyd Jones brings to ... and business development experience.   Most recently, Mr. Lloyd ...
(Date:5/6/2015)... BOSTON, May 6, 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: ... financial results for the three-month period ended March 31, ... were $8.3 million, an increase of 19% as compared ... , Product revenues increased 41% year-over-year, enabled by ... shipments to Merck Serono in the fourth quarter of ...
Breaking Medicine Technology:Galmed Pharmaceuticals First Quarter 2015 Conference Call and Webcast Scheduled for Wednesday, May 13, 2015 2Galmed Pharmaceuticals First Quarter 2015 Conference Call and Webcast Scheduled for Wednesday, May 13, 2015 3Neuralstem Appoints Jonathan Lloyd Jones as Chief Financial Officer 2Neuralstem Appoints Jonathan Lloyd Jones as Chief Financial Officer 3Neuralstem Appoints Jonathan Lloyd Jones as Chief Financial Officer 4Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 2Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 3Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 4Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 5Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 6Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 7Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 8Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 9Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 10Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 11
(Date:5/6/2015)... San Mateo, Calif. (PRWEB) May 06, 2015 ... SafeMonk today announced a strategic partnership to ... in the cloud. The two industry-leading companies are teaming ... encryption platform. , “We’re thrilled to welcome ... meaningful to us that the people behind SafeMonk, the ...
(Date:5/6/2015)... Aging2.0 - the global network ... lineup of speakers and sponsors for its second annual ... for May 18-19 in San Francisco, brings together a ... investors and more than 50 startups from around the ... new products and services for the aging population. ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 In celebration of ... wigs giveaway. Every month they will give away a deluxe ... They listed a few steps to enter on a third-party ... at random, so anyone can be the winner. , The ... PremierLaceWigs.com has been the destination for such a jewel for ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 The American ... nomination period for its prestigious Integrated Water Resources Management ... IWRM approach to water resources projects. , An IWRM approach ... our establishment in 1964. In 2014, 12 projects were nominated ... IMPACT magazine features not only the 2014 AWRA IWRM Award ...
(Date:5/6/2015)... May 06, 2015 The Jefferson ... dedicated to activating and celebrating public service, announced ... Highmark Health, as an Outstanding Employee Volunteer Organization. ... Jefferson Awards Foundation, are dedicated to building a ... a decade, Highmark Health has recognized employees who ...
Breaking Medicine News(10 mins):Health News:Sookasa Grows Globally With SafeMonk Partnership 2Health News:Sookasa Grows Globally With SafeMonk Partnership 3Health News:Aging2.0 Global Innovation Summit Provides Unique Forum to Discover New Technologies and Develop Partnerships in the Senior Care Market 2Health News:Aging2.0 Global Innovation Summit Provides Unique Forum to Discover New Technologies and Develop Partnerships in the Senior Care Market 3Health News:Aging2.0 Global Innovation Summit Provides Unique Forum to Discover New Technologies and Develop Partnerships in the Senior Care Market 4Health News:PremierLaceWigs.com Human Hair Lace Wigs Giveaway Could Change Your Hairstyle 2Health News:Nominations Sought for Integrated Water Resources Management (IWRM) Award 2Health News:The Jefferson Awards Foundation Honors Highmark Health 2Health News:The Jefferson Awards Foundation Honors Highmark Health 3Health News:The Jefferson Awards Foundation Honors Highmark Health 4
... DCM is a condition which occurs when the heart becomes ... blood efficiently. The condition affects 35 in every 100,000 people. ... study published in the journal Science that a defect in ... key role in regulating the flow of calcium through the ...
... the Johns Hopkins School of Public Health has caused concerns ... urgent research into the impact of soya on unborn children ... can damage the male reproductive organs. Though there is no ... its effects on rats were so severe that// researchers believe ...
... in blood has been believed to be the ... of heart disease is associated with increased levels ... between LDL(Low-Density Lipoprotein)or 'bad' cholesterol and HDL(High-Density Lipoprotein) ... However, researchers in Canada and Sweden are now ...
... killers and both in developed and developing countries heart ... lost - through premature death and disability. Researchers at ... of measures that could reduce the number of years ... measures could be divided// into non-personal and personal. Non-personal ...
... ghrelin, has been identified by researchers from the Oregon ... of the hormone on the brain and have shown ... hypothalamus involved in weight regulation. Ghrelin is a hormone ... feeding when introduced to specialized weight regulating brain cells ...
... A recent study by researchers at the University of Durham ... benefit to the long list of already existing ones, for ... are at much less risk of being smothered than babies ... and their babies who were filmed at night while they ...
Cached Medicine News:Health News:Scientists locate key hormone involved in appetite control 2
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Inquire...
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
Medicine Products: